University of California, San Diego
The purpose of this study is to examine the effects of combined intranasal esketamine with brief cognitive behavioral therapy for suicide prevention (BCBT-SP) for suicidal ideation (SI) in patients with treatment- resistant depression (TRD). The secondary aim is to identify the biological targets of treatment response using combined transcranial magnetic stimulation and electroencephalography (TMS-EEG). In this project we will recruit patients between the ages of 18 and 70, diagnosed with a major depressive episode with ongoing suicidal ideation present who have failed (or not shown signs of improvement) after at least one prior treatment. The null hypothesis is that there will be no difference in reductions in suicidality at 1-week post-treatment between the combined treatment group and the ketamine only treatment group. The alternative hypothesis is that the combined treatment will result in a greater reduction in suicidal ideation at 1-week post-treatment.
Inclusion Criteria: 1. All genders 2. Ages 18 to 70 years 3. Physician order of intranasal esketamine in the UCSD Interventional Psychiatry Clinic 4. Treatment resistant depression diagnosis confirmed by the ordering physician (treatment failure defined as the lack of clinically meaningful response in depression following an antidepressant trial) 5. Ongoing SI present beyond the screening phase of the study (confirmed with Beck SSI score ≥4). 6. Pass the TMS adult safety screening (TASS) questionnaire 7. Voluntary outpatients capable to consent to treatment and seen at the UC San Diego Health…
Naturalistic Intranasal Esketamine is administered in accordance with psychiatrist recommendations
12 session evidence based psychotherapy protocol with weekly 50 minute sessions
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.